Emily Kinsey, MD
Hospitalist · Richmond, VANPI 1770826026
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 32.2% of the total. 2025 is the largest year on record at $2,901, more than ten times the $123 reported in 2019. Among hospitalist clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 89 payments — averaging $57.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$2K
- AstraZeneca$1K
- Intera Oncology, Inc$331
- Novartis$242
- Galvanize Therapeutics, Inc$186
- Dendreon Pharmaceuticals LLC$123
- plus $1K from 32 others
Across 13 payments — averaging $3468.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$43K
- GSK$2K
What the payments were for
- Consulting fees$1,34026%
- Travel & lodging$1,23924%
- Food & beverage$2,47448%
- Education$671%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 15 | $1,646 |
| AstraZeneca | 3 | $1,382 |
| Intera Oncology, Inc | 2 | $331 |
| Novartis | 10 | $242 |
| Galvanize Therapeutics, Inc | 2 | $186 |
| Dendreon Pharmaceuticals LLC | 1 | $123 |
| Johnson & Johnson | 5 | $93 |
| E.r. Squibb & Sons, L.L.C. | 5 | $83 |
| Tempus AI, Inc | 1 | $83 |
| Sanofi | 3 | $73 |
| Gilead(2 entities) | 3 | $68 |
| GSK | 1 | $67 |
| Genentech USA, Inc. | 2 | $60 |
| Tersera Therapeutics LLC | 2 | $50 |
| Eisai Inc. | 3 | $50 |
| Regeneron Healthcare Solutions, Inc. | 2 | $41 |
| Taiho Oncology, Inc. | 2 | $38 |
| Astellas Pharma US Inc | 2 | $36 |
| Pfizer | 2 | $36 |
| Amgen | 2 | $35 |
| Puma Biotechnology, Inc. | 2 | $34 |
| CTI Biopharma Corp. | 1 | $33 |
| Boehringer Ingelheim | 1 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $26 |
| Deciphera Pharmaceuticals Inc. | 2 | $25 |
| Mirati Therapeutics, Inc. | 1 | $23 |
| Sobi, Inc | 1 | $23 |
| Merck | 1 | $21 |
| G1 Therapeutics, Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Servier Pharmaceuticals LLC | 1 | $16 |
| Incyte Corporation | 1 | $16 |
| EMD Serono, Inc. | 1 | $15 |
| Apellis Pharmaceuticals, Inc. | 1 | $15 |
| Bristol Myers Squibb | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZIIHERA$800
- INTERA$331
- ALIYA SYSTEM$130
- PROVENGE$123
How this compares
$5,120 in reported general payments places this provider in the 95th percentile of 539 hospitalist providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $7,514 |
| Ondansetron Hcl | 50 | $966 |
| Letrozole | 18 | $831 |
| Potassium Chloride | 14 | $578 |
| Dexamethasone | 21 | $545 |
| Prochlorperazine Maleate | 50 | $441 |
| Mirtazapine | 20 | $289 |
| Oxycodone Hcl | 32 | $270 |
| Duloxetine Hcl | 12 | $167 |
| Prednisone | 20 | $112 |
| Tramadol Hcl | 11 | $35 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $36 | $7,51411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 539 hospitalist providers in Virginia.
Other hospitalist in Richmond
- Ishan PatelRichmond$853
- Anusha KanagalaRichmond$666
- Ruksana JabeenRichmond$595
- Yuri MaricichCharlottesville$212K
- Dennis NguyenSpringfield$8K
- Muhammad AfridiWinchester$7K
- Lana WahidRoanoke$6K
- Mohammed AmerNewport News$5K
- Jill CouchNorton$3K
- John MelsonCharlottesville$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.